SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2012 / Cilt: 12 - Sayı: 8

İlaç kaplı stentler: Mevcut durum ve yeni gelişmeler

Drug eluting stents: Current status and new developments

Gökhan ERTAŞ
Heleen Van BEUSEKOM
Pages
676–683
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The present review discussed current drug eluting stents and new developments. (Anadolu Kardiyol Derg 2012; 12: 676-83)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Despite the favorable impact of drug eluting stents on stent restenosis, their long-term reliability is considered worrisome by some because of stent thrombosis.
📊
Key Findings & Data:Often attributed to adverse reactions to the stent platform, both the drugs and polymer characteristics have been further advanced with current technologies.
💡
Conclusion & Impact:The present review discussed current drug eluting stents and new developments. (Anadolu Kardiyol Derg 2012; 12: 676-83)
🔬Design:Review & Systematic Survey
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Despite the favorable impact of drug eluting stents on stent restenosis, their long-term reliability is considered worrisome by some because of stent thrombosis. Often attributed to adverse reactions to the stent platform, both the drugs and polymer characteristics have been further advanced with current technologies. The present review discussed current drug eluting stents and new developments. (Anadolu Kardiyol Derg 2012; 12: 676-83)

Özet

İlaç kaplı stentlerin stent restenozundaki olumlu sonuçlarının yanında stent trombozu nedeniyle uzun dönem güvenirliği endişe oluşturmaktadır. Stent platformunun olumsuz etkileri ile ilişkilendirilse de, ilaçlar ve polimer özellikleri yeni teknolojiler ile daha da geliştirilmiştir. Bu derlemede mevcut ilaç kaplı stentler ve yeni gelişmeleri tartıştık. (Anadolu Kardiyol Derg 2012; 12: 676-83)

🔖

Cite This Article

ERTAŞ, G., BEUSEKOM, H. V. (2022). İlaç kaplı stentler: Mevcut durum ve yeni gelişmeler. Anadolu Kardiyoloji Dergisi, Cilt: 12 - Sayı: 8, 676–683. https://ajindex.com/articles/436364

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316: 701-6
  2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489-95
  3. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-9
  4. Alfonso F, Perez-Vizcayno MJ, Cruz A, Garcia J, Jimenez-Quevedo P, Escaned J, et al. Treatment of patients with in-stent restenosis. EuroIntervention 2009; 5: D70-8
  5. Regar E, Sianos G, Serruys PW. Stent development and local drug delivery. Br Med Bull 2001; 59: 227-48
  6. Regar E, Serruys PW, Bode C, Holubarsch C, Guermonprez JL, Wijns W, et al; RAVEL Study Group. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002; 106: 1949-56
  7. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006; 47: 2108-11
  8. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202
  9. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008
  10. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: 937-48
  11. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two- institutional cohort study. Lancet 2007; 369: 667-78
  12. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice.4-year results f